Abstracts

CMV Viraemia Is Associated With Mortality Among Children With HIV Starting ART in Sub-Saharan Africa

Background: Cytomegalovirus (CMV) co-infection is associated with mortality in adults with HIV, but the association between CMV viraemia and mortality in children with HIV is uncertain. Methods: In 497 children enrolled in the ARROW trial (registry number ISRCTN24791884) in Uganda and Zimbabwe, CMV was quantified using real-time polymerase chain reaction (PCR) at antiretroviral therapy (ART)…

Persistent Viremia With vpr/tat-Deleted HIV and No T-Cell Responses to HLA-Predicted HIV Peptides

Background: Two children, P1 and P2, living with HIV have persistent low-level viremia (LLV) despite adherence to ART documented by directly-observed-therapy and/or therapeutic drug monitoring. We hypothesized that their persistent viremia was due to clones of HIV-infected cells harboring HIV epitopes that escaped immune surveillance. Methods: Plasma HIV RNA was monitored. Blood RNA and DNA…

High Drug Exposures in Neonates Using ABC/3TC Dispersible Tablets During the First Week of Life

Background: Pediatric fixed dose combination (FDC) formulations are preferred for infants and young children but rapid maturation of metabolic and elimination pathways complicate their use in neonates. We previously reported the pharmacokinetics (PK) and safety of abacavir/lamivudine (ABC/3TC) FDC dispersible tablet in neonates but no PK data were available prior to 6 days of life.…

Pediatric PBPK Scaling Model for a New Long-Acting, 3 HIV Drug Combination in a Single Injection

Background: The TLC-ART program successfully engineered lopinavir (LPV), ritonavir (RTV), and tenofovir (TFV) in a single 3-drug long-acting (LA) injectable suspension (TLC-ART 101) that has undergone scale-up, stability and preclinical safety studies. A First-in-Human study (NCT06850728) is ongoing. Leveraging juvenile and adult non-human primate (NHP) data, we developed and validated physiologically based pharmacokinetic models (PBPK)…